article thumbnail

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.

article thumbnail

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

SOURCE InMed Pharmaceuticals Inc. InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

Cannabis Law Report

IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. POTOMAC, Md.–(BUSINESS

article thumbnail

Tryp Therapeutics Announces Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

Cannabis Law Report

The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.

article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol. .

article thumbnail

Press Release: Biomind Labs Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer’s Disease With a Proprietary formulation Based On 5-MeO-DMT

Cannabis Law Report

(“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce that it has commenced a Phase II clinical trial for its proprietary […] (..)

article thumbnail

Prohibition Publish 2nd Ed Of The Pharmaceutical Cannabis Report

Cannabis Law Report

Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment, however regulations are constantly shifting beneath the feet of operators and their ability to serve patients depends on their capacity to navigate a changing landscape of governance.